Bosh sahifa0775 • HKG
add
CK Life Sciences Intl (Holdings) Inc
Yopilish kursi
0,51 $
Kunlik diapazon
0,48 $ - 0,51 $
Yillik diapazon
0,30 $ - 0,74 $
Bozor kapitalizatsiyasi
4,61 mlrd HKD
Oʻrtacha hajm
6,86 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
HKG
Bozor yangiliklari
CNBC
1 soat oldin
Stock futures are little changed after S&P 500 slips from record highs:
Live updates
0,76%
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (HKD) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 1,32 mlrd | 2,20% |
Joriy xarajat | 323,51 mln | -4,23% |
Sof foyda | 500,50 ming | -97,29% |
Sof foyda marjasi | 0,04 | -97,20% |
Har bir ulushga tushum | — | — |
EBITDA | 117,12 mln | 36,03% |
Amaldagi soliq stavkasi | 79,96% | — |
Balans
Jami aktivlari
Jami passivlari
| (HKD) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 562,09 mln | 11,10% |
Jami aktivlari | 10,89 mlrd | -1,45% |
Jami passivlari | 6,87 mlrd | -0,11% |
Umumiy kapital | 4,01 mlrd | — |
Tarqatilgan aksiyalar | 9,61 mlrd | — |
Narxi/balansdagi bahosi | 1,21 | — |
Aktivlardan daromad | 1,75% | — |
Kapitaldan daromad | 1,91% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (HKD) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 500,50 ming | -97,29% |
Operatsiyalardan naqd pul | 72,70 mln | 80,63% |
Sarmoyadan naqd pul | -47,88 mln | -484,81% |
Moliyadan naqd pul | -77,72 mln | 41,39% |
Naqd pulning sof oʻzgarishi | -57,56 mln | 42,02% |
Boʻsh pul | 35,56 mln | 91,21% |
Haqida
CK Life Sciences International Inc., or CK Life Sciences, is a subsidiary of CK Hutchison Holdings. It is engaged in research and development, commercialization, marketing and sale of biotechnology products. The chairman is Mr. Victor Li, the elder son of Mr. Li Ka-shing, the chairman of Cheung Kong Holdings.
It was established in 2000 and listed on the Hong Kong Stock Exchange via Growth Enterprise Market in 2002. It was transferred to Main Board of the Hong Kong Stock Exchange in 2008.
CK Life Sciences has operations in Australia, and in 2012 acquired an Australian salt company as part of its expansion into the agricultural sector.
The company divested its Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics for $100 million in October 2024. Wikipedia
CEO
Tashkil etilgan
2000
Xodimlar soni
1 968
